KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accounts Payables: 2011-2025

Historic Accounts Payables for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $94.0 million.

  • Sarepta Therapeutics' Accounts Payables fell 20.85% to $94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.0 million, marking a year-over-year decrease of 20.85%. This contributed to the annual value of $214.4 million for FY2024, which is 30.03% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Accounts Payables stood at $94.0 million for Q3 2025, which was down 31.23% from $136.7 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Accounts Payables ranged from a high of $214.4 million in Q4 2024 and a low of $44.2 million during Q3 2021.
  • Moreover, its 3-year median value for Accounts Payables was $109.8 million (2023), whereas its average is $126.2 million.
  • Over the last 5 years, Sarepta Therapeutics' Accounts Payables had its largest YoY gain of 188.22% in 2021, and its largest YoY loss of 40.74% in 2021.
  • Over the past 5 years, Sarepta Therapeutics' Accounts Payables (Quarterly) stood at $76.7 million in 2021, then climbed by 24.93% to $95.9 million in 2022, then spiked by 72.01% to $164.9 million in 2023, then skyrocketed by 30.03% to $214.4 million in 2024, then decreased by 20.85% to $94.0 million in 2025.
  • Its last three reported values are $94.0 million in Q3 2025, $136.7 million for Q2 2025, and $156.1 million during Q1 2025.